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Chronic granulomatous disease (CGD) is caused by defects of NADPH oxidase. 
The diagnosis of CGD can be made by analysis of NADPH oxidase activity, however, 
identification of the CGD subgroups is required before performing mutation analysis. The 
membrane-bound subunits, gp91phox and p22phox, can be quickly analyzed by flow 
cytometry, unlike the cytosolic components, p47phox and p67phox. We evaluated the 
feasibility of flow cytometric detection of p47phox and p67phox with specific 
monoclonal antibodies in two patients with p47phox deficiency and 7 patients with 
p67phox deficiency. Consistent with previous observations, p47phox and p67phox were 
expressed in phagocytes and B cells, but not in T or natural killer cells, from normal 
controls. In contrast, patients with p47phox and p67phox deficiency showed markedly 
reduced levels of p47phox and p67phox, respectively. These techniques will be useful to 
rapidly assess the expression of the cytosolic components, p47phox and p67phox, and 











Chronic granulomatous disease (CGD) is a primary immunodeficiency disease of 
phagocytes caused by defects of nicotinamide dinucleotide phosphate (NADPH) oxidase 
[1, 2]. NADPH oxidase is an enzyme responsible for the production of reactive oxygen 
species that are needed to kill pathogenic bacteria and fungi. Patients with CGD have 
increased susceptibility to infections, as well as hyperinflammation and granuloma 
formation at sites of infection [3]. The NADPH oxidase is a multicomponent system 
including a membrane-bound flavocytochrome b558, comprised of gp91phox and 
p22phox, cytosolic components, comprised of p40phox, p47phox, and p67phox, and a 
small GTP-binding protein comprised of Rac1 or Rac2 [1, 2]. About 70% of CGD cases 
are caused by mutations in the CYBB gene that encodes gp91phox and is located at 
Xp21.1 [4]. The remaining 30% of cases include four other subgroups of the disease, all 
of which are inherited in an autosomal recessive manner [1, 2]. Mutations in the NCF1 
gene cause p47phox deficiency, the second most common subtype of CGD, which 
accounts for 25% of CGD patients. The other cases occur due to mutations in the NCF2, 
CYBA, or NCF4 genes that encode p67phox, p22phox, or p40phox, respectively. To date, 
p40phox deficiency has only been reported in one individual [5]. 
A diagnosis of CGD can be achieved by measurement of neutrophil superoxide 
production via NADPH oxidase. The most recognized test is the nitroblue tetrazolium test, 
which is based on visual inspection of phagocytes. Because of its high reliability and 
sensitivity, the dihydrorhodamine (DHR) assay using flow cytometry has largely replaced 
the nitroblue tetrazolium test in many laboratories [6]. Despite the need for specific 
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technical skills, the DHR assay is able to distinguish between patients with absent to 
greatly diminished production of superoxide, which is commonly observed in males with 
X-linked CGD and patients with residual superoxide production, which is frequently 
observed in autosomal recessive and variant X-linked CGD [1, 2]. However, further 
identification of CGD subgroups is necessary before genetic analysis, which is often 
labor-intensive and time-consuming. The membrane-bound subunits, gp91phox and 
p22phox, can be analyzed by flow cytometry using monoclonal antibodies (mAbs), such 
as 7D5 that identifies the extracellular domain of flavocytochrome b558 [7, 8]. In contrast, 
the cytosolic components, p47phox and p67phox, are usually investigated by immunoblot 
analysis that requires a large sample of blood and takes longer to perform. We therefore 
assessed the feasibility of flow cytometric analysis of intracellular p47phox and p67phox 




Materials and methods 
 
Patients 
We studied 9 affected patients with autosomal recessive CGD: 2 with p47phox 
deficiency and 7 with p67phox deficiency. All patients but p67-4 were born to non-
consanguineous Japanese parents. We also evaluated 3 patients with X-linked CGD 
(gp91phox deficiency) and 10 healthy adult volunteers. Case presentations of patient p47-
1 and p47-2 and the sibling cases of p67-1.1 and p67-1.2 have been reported elsewhere [9, 
10]. Patients p67-2.1 and p67-2.2 were also sibling cases. Approval for the study was 
obtained from the Human Research Committee of Kanazawa University Graduate School 
of Medical Science, and informed consent was obtained in accordance with the 
Declaration of Helsinki. 
 
Flow cytometry 
For the analysis of p47phox and p67phox expression, peripheral blood 
mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque gradient centrifugation 
from patients and controls immediately after blood collection or after overnight shipment 
at ambient temperature. Granulocytes were recovered from the pellet of the gradient after 
lysis of any erythrocytes. PBMCs were stained for cell-surface antigens before cell 
membrane permeabilization using the following mAbs: fluorescein isothiocyanate-
conjugated anti-CD14 and anti-CD56; phycoerythrin-Cy5-conjugated anti-CD20 and 
anti-CD3 (all from Becton Dickinson, San Diego, CA). Granulocytes were stained with 
fluorescein isothiocyanate-conjugated anti-CD16b mAb (Beckman Coulter, Fullerton, 
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CA). After washing, cells were fixed and permeabilized with Cytofix/Cytoperm Plus kit 
(Becton Dickinson) and were incubated with anti-p47phox (clone 1, Becton Dickinson), 
anti-p67phox mAb (clone D-6, Santa Cruz Biotechnology Inc, Santa Cruz, CA) or 
purified mouse IgG1 (Becton Dickinson) at 4°C for 20 min. Cells were then reacted with 
phycoerythrin-conjugated anti-mouse IgG1 (Southern Biotech, Birmingham, AL) at 4°C 
for 20 min. Stained cells were analyzed with a FACSCalibur flow cytometer using 
CellQuest software (BD Bioscience, Tokyo, Japan) [11]. Because the anti-p47phox and 
anti-p67phox mAbs belong to the mouse IgG1 subclass, all antibodies for surface staining 
were chosen from mouse IgG2 or IgM to avoid cross-reaction. For analysis of gp91phox 
and p22phox, whole blood was stained with 7D5 mAb (MBL, Nagoya, Japan). 
 
Analysis of the production of reactive oxygen species 
Peripheral blood was loaded with 1 µM of DHR 123 at 37˚C for 5 min, and 
stimulated with 100 ng/mL of phorbol myristate acetate at 37˚C for 30 min. After lysis of 
erythrocytes, production of reactive oxygen species of granulocytes was quantified by 
measuring intracellular rhodamine using flow cytometry, as previously described [9, 12]. 
 
Mutation analysis of NCF1 and NCF2 
DNA was extracted from blood samples using standard methods. The NCF1 and 
NCF2 genes were amplified from specific primers as previously described [9]. 
Sequencing was performed on purified polymerase chain reaction products using the ABI 
Prism BigDye Terminator Cycle sequencing kit on an ABI 310 or 3100 automated 




Mutation analysis and ROS production 
Table 1 presents the clinical and sequencing data of the patients. Patients p67-2.1 
and p67-2.2 were compound heterozygotes bearing Gln260X and Arg395Trp mutations 
in NCF2. The former is a novel nonsense mutation. Two distinct NCF2 mutations, 
Tyr394Asp and Asp408fs, were demonstrated in patient p67-3. The effect of the novel 
missense mutation Tyr394Asp was evaluated using the web-based analysis tool, 
Mutation@A Glance (http://rapid.rcai.riken.jp/mutation/) [14], and was found to be 
deleterious on the basis of the SIFT program [15]. Patient P67-5 was a compound 
heterozygote bearing Trp22X and Arg102X mutations. The former is a novel nonsense 
mutation. 
Upon stimulation with phorbol myristate acetate, DHR-loaded neutrophils from 
normal controls showed significant increases in fluorescence with tight peaks. Patients 
with gp91phox deficiency exhibited virtually no neutrophil DHR activity. In contrast, 
patients with p47phox or p67phox deficiency exhibited variable activity ranging from 
almost none to a moderate increase in the fluorescence after stimulation with 
characteristic wider peaks compared with those found in gp91phox deficiency. 
 
Intracellular expression of p47phox and p67phox 
Consistent with previous observations [2], p47phox and p67phox were expressed 
intracellularly in phagocytes and B cells, but not in T or natural killer (NK) cells, from 
normal controls (Fig. 1). This pattern of lineage-specific expression was the same as that 
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observed for gp91phox expression. However, we observed a marked difference in 
p47phox or p67phox expression among neutrophils, monocytes and B cells, which was in 
contrast to the expression of gp91phox. The p47phox levels in neutrophils were relatively 
low compared with monocytes and B cells, whereas the p67phox levels in B cells were 
considerably lower compared with neutrophils and monocytes. Because neutrophils 
exhibited decreased viability and tended to aggregate after overnight shipment and cell 
isolation, we decided to use PBMCs for intracellular staining of p47phox and p67phox in 
clinical samples in order to avoid non-specific staining that might lead to misdiagnosis. 
The patients with p47phox deficiency exhibited markedly reduced levels of 
p47phox expression in both monocytes and B cells (Fig. 2). Conversely, the patients’ 
monocytes and B cells expressed p67phox at levels that were comparable to normal 
controls. On the other hand, the patients with p67phox deficiency exhibited considerably 
reduced levels of p67phox expression in monocytes and B cells (Fig. 2). Although the 
expression of p47phox in the monocytes appeared to be marginally decreased, p47phox 
expression in the patients’ B cells was comparable to normal controls. Expression of the 
membrane-bound component, gp91phox, determined by 7D5 mAb, was normal in all 
patients with p47phox and p67phox deficiency. 
 
Expression of p47phox or p67phox in carrier parents 
To evaluate the ability of our flow cytometric analysis technique to detect carriers, 
we examined p47phox expression in monocytes from the parents of p47-1 and p67phox 
expression in monocytes from the mother of p67-2.1 and p67-2.2 and the parents of p67-
3, all of whom were heterozygous carriers (Fig. 3). The pattern of DHR and gp91phox 
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expression from the mother of gp91-1 showed a bimodal distribution consistent with her 
obligate X-linked CGD carrier status. In contrast, and consistent with previous reports [2], 
the NADPH oxidase activities of neutrophils from carriers of the p47phox and p67phox 
deficiency were normal. The expression of p47phox or p67phox in their monocytes 




 In the present study, we have developed practical flow cytometric assays for 
p47phox and p67phox. Although analysis of the expression of the individual subunits by 
flow cytometry has been described previously [16], our approach differs from it on two 
counts. First, we used commercially available mAbs that are specific for p47phox and 
p67phox. This potential advantage may allow the assay to be widely used in many 
laboratories. Second, we analyzed the intracellular expression of p47phox and p67phox in 
monocytes and B cells, as well as in neutrophils. B cells contain all of the components of 
the phagocyte NADPH oxidase and generate superoxide in response to a variety of 
stimuli; albeit at a lower level than neutrophils [17]. Our lineage-specific analysis may 
provide more accurate and reliable data. Previous studies using Western blot analysis 
have demonstrated that p47phox and p67phox expression in B cells were reduced by 
about 6 and 70%, respectively, compared with neutrophils [17]. The reasons neutrophils 
from normal individuals exhibited lower levels of p47phox compared with monocytes 
and B cells in our assay are presently unclear. Further studies using other anti-p47phox 
antibodies that recognize different epitopes will be necessary to resolve this issue.  
 The NADPH subunits including p47phox, p67phox and p40phox exist as a tight 
complex in the cytoplasm in the resting state [18]. However, loss of one of the p47phox 
or p67phox proteins did not generally affect the expression of the other, unlike the 
membrane-bound components, gp91phox and p22phox. Because gp91phox and p22phox 
act to stabilize each other, and the absence of either protein generally leads to down-
regulation of the other [19, 20]. In fact, the 7D5 mAb that binds exclusively to an 
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extracellular domain of gp91phox has been proven not to stain the cell surface on 
neutrophils deficient in p22phox, thus indicating its screening capability for both 
gp91phox and p22phox deficiency [8]. Therefore, the combined flow cytometric analysis 
of the surface staining by 7D5 mAb and our assay for intracellular p47phox and p67phox 
would be a valuable tool for detecting subgroups of CGD. 
 Mutations in the gp91phox gene cause X-linked CGD and account for 
approximately 70% of all cases [4]. The remaining 30% are due to mutations in the other 
subunit and are inherited in an autosomal recessive manner [1]. In Japan, p47phox-
deficient CGD has been documented in relatively few patients, unlike Western countries 
[21]. Because of the infrequency of such diseases, our study was limited to include a 
small number of patients, in particular, those with p47phox deficiency. However, the vast 
majority of patients with p47phox deficiency carry the homozygous 2-bp deletion in the 
NCF1 gene, which was also detected in our patients. This mutation results from 
recombination events between the wild-type gene and the pseudogene [22, 23]. Patients 
with this mutation have been reported to exhibit undetectable levels of p47phox protein 
expression [23], which was consistent with our results. On the other hand, although a 
variety of mutations in the NCF2 gene have been demonstrated in patients with p67phox 
deficiency, the p67phox protein appears to be undetectable by Western blot analysis in 
most cases [23]. Interestingly, the p67phox protein was absent in patients p67-1.1, p67-
1.2, p67-2.1, p67-2.2, p67-4 and p67-5, whereas residual p67phox expression was 
detected in patient p67-3 who exhibited the significant remaining NADPH oxidase 
activity. It should be noted that there are mutations in the NCF1 or NCF2 genes that leave 
the protein expression intact but destroy the enzymatic activity [23]. In such cases, albeit 
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rare, our flow cytometric analysis of protein expression as well as Western blot analysis 
cannot contribute to identification of the CGD subgroups, and mutation analysis is 
required. Further investigations will be required to assess the sensitivity and limitations of 
the assay and its utility in determining the phenotype-genotype correlation. 
 Most female carriers of X-linked CGD can be identified by flow cytometry. A 
mosaic pattern of oxidase-positive and -negative neutrophils from the basis of the DHR 
assay or analysis of gp91phox expression is observed due to random X-chromosome 
inactivation. In contrast, the detection of carriers of autosomal recessive CGD is usually 
performed by genetic analysis. It is well known that the NADPH oxidase activity is 
normal in obligate carriers [2]. The expression of p47phox and p67phox proteins, 
assessed by Western blot analysis, has also been reported to likely be normal in carriers 
of p47phox and p67phox deficiency, respectively [2]. Our flow cytometric analysis 
demonstrated slightly decreased expression of p47phox and p67phox in monocytes from 
obligate carriers of p47phox and p67phox deficiency, respectively, compared with 
normal controls. However, these subtle differences of protein expression do not allow the 
detection of carriers in the clinical settings. Therefore, genetic testing remains appropriate 
for identification of carriers of autosomal recessive CGD. 
In summary, our study demonstrated rapid and sensitive detection of intracellular 
p47phox and p67phox by flow cytometry, which is useful as a secondary screening test 
for CGD. This technique would be also valuable in the evaluation of chimerism in 
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Table 1   Clinical and sequencing data 
 
 
Subjects Age a Clinical features Gene  Nucleotide      Effect 
      mutation 
 
p47-1  31 y Skin infections, NCF1  73_74delGT d      Tyr26fs 
   otitis, colitis 
 
p47-2  13y BCGitis  NCF1  73_74delGT      Tyr26fs 
   Williams syndrome   7q11.23 deletion 
 
p67-1.1 b 8 y Perianal abscess, NCF2  1223delA d      Asp408fs 
   lymphadenitis 
 
p67-1.2 b 2 y Perianal abscess NCF2  1223delA d      Asp408fs 
 
 
p67-2.1c 1 mo Aspergillus  NCF2  778C>T      Gln260X 
   pneumonia    1183C>T      Arg395Trp 
 
p67-2.2 c 3 y Sepsis   NCF2  778C>T      Gln260X 
        1183C>T      Arg395Trp 
 
p67-3  6 mo Aspergillus  NCF2  1180T>G      Tyr394Asp 
   pneumonia    1223delA      Asp408fs 
 
p67-4  10 m BCGitis  NCF2  304C>T d      Arg102X 
 
p67-5  5 y BCGitis  NCF2  66G>A      Trp22X 
   lymphadenitis    304C>T      Arg102X 
 
 
a Data at the time of sample collection.  
b, c Sibling cases. 






Figure 1   Expression of p47phox, p67phox and gp91phox in blood leukocyte 
populations from normal individuals.  
Shown are the results of intracellular expression of p47phox (top) and p67phox (middle), 
and surface expression of gp91phox analyzed by 7D5 mAb (bottom) in CD16b+ 
neutrophils, CD14+ monocytes, CD3+ T, CD20+ B, and CD56+ NK cells from a healthy 
control. Thin lines indicate control Ab; thick lines represent mAbs specific for the 
NADPH subunits. 
 
Figure 2   Analysis of DHR and expression of p47phox, p67phox and gp91phox in 
CGD patients. 
In the DHR assay, granulocytes were analyzed using DHR 123 as a fluorescent probe 
before (thin lines) and after (thick lines) stimulation with phorbol myristate acetate. 
Expression of gp91phox in granulocytes, as assessed using 7D5, and expression of 
p47phox and p67phox in CD14+ monocytes and CD20+ B cells are shown. 
 
 
Figure 3   DHR assay and expression of p47phox or p67phox in carrier parents. 
Rhodamine expression in unstimulated and phorbol myristate acetate-stimulated 
granulocytes obtained from obligate carriers. Expression of gp91phox analyzed using 
7D5 in granulocytes and the expression of p47phox or p67phox in CD14+ monocytes are 
shown. 
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